# Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

> **NCT06553872** · PHASE2 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 60 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Pirtobrutinib
- **DRUG:** Brexucabtagene Autoleucel

## Key facts

- **NCT ID:** NCT06553872
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-23
- **Primary completion:** 2029-08
- **Final completion:** 2029-08
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06553872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06553872, "Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06553872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*